ERAS - long - breakout - upcoming catalysts

24 Feb

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

This is not a financial advice!

2 upcoming catalysts on 30rd of June and even more in 1Q and 2Q - 2024

Pretty high volume recently with Triangle breakout and pullback

We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.

Keep an eye on 3.00, 3.30 and 4.50 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.

SL under 1.80

TP approx. 7.0

Most info on the chart.

Trade carefully!